American Society of Hematology

Morning Symposia

The following symposia took place prior to the 2017 ASH Annual Meeting. View the FSS Guidelines to learn about hosting a symposium in 2018.

Friday, December 8, 7:00 a.m. - 11:00 a.m.

Friday Satellite Symposia (FSS) will take place on Friday, December 8, 2017, preceding the ASH annual meeting. ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs.

Program Chair:

Mehdi Hamadani, MD, Medical College of Wisconsin
Milwaukee, WI

Advances in the Management of Chronic Lymphocytic Leukemia and Other B-Cell Lymphomas

Friday, December 8, 2017, 7:00 a.m. - 11:00 a.m.
Marriot Marquis Atlanta, A703-A704

Register now

This program is sponsored by North American Center for Continuing Medical Education and supported by Teva Pharmaceuticals.

A multidisciplinary panel of experts will convene to provide the latest clinical evidence on newer/emerging treatment used to overcome challenges within the management of CLL and other B-cell lymphomas.

Chair:

Chadi Nabhan, MD, MBA
Cardinal Health Specialty Solutions
Chicago, IL

Speakers:

Matthew J. Matasar, MD, MS
Memorial Sloan Kettering Cancer Center
New York, NY

Anthony R. Mato, MD
University of Pennsylvania
Philadelphia, PA

Val R. Adams, PharmD
University of Kentucky
Lexington, KY

Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC
Fox Chase Cancer Center
Philadelphia, PA

Contact:

Jennifer Browne
North American Center for Continuing Medical Education
Phone: 609-630-6204
Email: jbrowne@naccme.com

back to top

Evidence- and Value-Based Approaches to Pathology and Laboratory Diagnosis and Prognosis of Common Hematologic Neoplasms: A Case-Based Illustration

Friday, December 8, 2017, 7:00 a.m. - 11:00 a.m.
Marriot Marquis Atlanta, Atrium A

Register now

This program is sponsored and supported by Mayo Clinic.

The recent advancements in the laboratory diagnosis and prognostication of hematologic neoplasms have created a knowledge gap for many practicing hematologists/oncologists and hematopathologists. This program’s overall objective is to update the practicing hematologists/oncologists and hematopathologists about the evolving repertoire of test options and appropriate testing strategies.

We aim to inform participants on the most cost-effective, diagnostically efficient testing strategies in the evaluation of hematologic malignancies. Using data-driven testing algorithms derived from the Mayo Clinic Hematopathology/Hematology practice and available literature, we will illustrate how unnecessary, redundant, and costly laboratory tests can be eliminated from the participants’ practices while maintaining the highest quality medical care.

Chair:

Rajiv K. Pruthi, MBBS
Mayo Clinic
Rochester, MN

Speakers:

Francis K. Buadi, MD
Mayo Clinic
Rochester, MN

Dragan Jevremovic, MD, PhD
Mayo Clinic
Rochester, MN

Ellen D. McPhail, MD
Mayo Clinic
Rochester, MN

Mrinal M. Patnaik, MD,MBBS
Mayo Clinic
Rochester, MN

Kaaren K. Reichard, MD
Mayo Clinic
Rochester, MN

David S. Viswanatha, MD
Mayo Clinic
Rochester, MN

Contact:

Sharon Preuss
Mayo Clinic
Phone: 507-284-8742
Email: preuss.sharon@mayo.edu

back to top

Improving MDS Outcomes From Diagnosis to Treatment: A Multidisciplinary Approach

Friday, December 8, 2017, 7:00 a.m. - 11:00 a.m.
Georgia World Congress Center, Bldg A- Lvl 4- A402-A403

Register now

This program is sponsored by The France Foundation in collaboration with the American Society of Pathology and supported by Celgene Corporation, American Society for Clinical Pathology.

This award winning, dynamic session offers participants a unique opportunity to learn from a multidisciplinary team of experts in hematology, oncology and hematopathology. Learners will make clinical decisions with the faculty as they review real life cases during this highly interactive and engaging activity.

Chair:

Amy E. DeZern, MD
Johns Hopkins University
Baltimore, MD

Speakers:

Steven D. Gore, MD
Yale School of Medicine
New Haven, CT

Dita Gratzinger, MD, PhD
Stanford University School of Medicine
Stanford, CA

Marilyn L. Slovak, PhD
University of New Mexico TriCore Reference Laboratories
Albuquerque, NM

Contact:

Amanda Noe
The France Foundation
Phone: 860-598-2282
Email: anoe@francefoundation.com

back to top

Individualizing Therapeutic Strategies for Patients With MDS

Friday, December 8, 2017, 7:00 a.m. - 11:00 a.m.
Georgia World Congress Center, Bldg B- Lvl 3- B308-B309

Register now

This program is sponsored and supported by MDS Foundation, Inc.

Recent developments in our knowledge of the immune system, the bone marrow micro-environment, and the genetic evolution of MDS are optimizing prognostication and management strategies. Intrinsic and extrinsic factors contributing to disease pathogenesis and influencing therapeutic response will be discussed.

Chairs:

Rena Buckstein, MD
Odette Cancer Center
Toronto, Canada

Mario Cazzola, MD
Fondazione IRCCS Policlinico San Matteo & University of Pavia
Pavia, Italy

Speakers:

Jude Fitzgibbon, PhD
Queen Mary University of London
London, United Kingdom

Rami S. Komrokji, MD
H. Lee Moffitt Cancer Center
Tampa, FL

Shahram Kordasti, MD, PhD
King's College Hospital NHS Foundation Trust
London, United Kingdom

John Koreth, MBBS, DPhil
Dana-Farber Cancer Institute
Boston, MA

Luca Malcovati, MD
University of Pavia Medical School
Piazzale Golgi, Italy

Contact:

Lea Harrison
MDS Foundation, Inc.
Phone: 1-609-298-1600 ext. 201
Email: lharrison@mds-foundation.org

back to top

Integrating Therapeutic Advances to Improve Current Practices in Myeloma Patient Care

Friday, December 8, 2017, 7:00 a.m. - 11:00 a.m.
Georgia World Congress Center, Bldg B- Lvl 5- Murphy BR 1-2

Register now

This program is sponsored by Penn State College of Medicine and supported by the Multiple Myeloma Research Foundation.

The clinical multiple myeloma (MM) arena has undergone significant advancement in recent years—not only in terms of available treatments but also in diagnosis and staging, minimal residual disease monitoring, and supportive care. This expansion of treatment options brings both opportunities and challenges. Although recent advances in MM treatment have led to improved median survival, the success has not been uniform. Some patients enjoy many years in clinical remission, whereas others have a poor prognosis with survival of only two or three years. This observation speaks to the heterogeneity of MM and the inappropriateness of a one-size-fits-all approach. Improving patient outcomes requires building on the foundation of current myeloma therapies with new agents and combinations, and it requires improving the understanding of the nature of the disease to provide patients with a more personalized approach to treatment.

This symposium will consist of a series of evidence-based presentations and interactive, patient-based video vignettes designed to stimulate audience engagement. Real-world case studies will provide an opportunity for learners to respond to practice-related issues and questions based on such factors as patient profile, clinical evidence, and assessment of risk/benefit to achieve the best possible durable response. IPad technology will also be utilized.

Chairs:

Paul G Richardson, MD
Dana-Farber Cancer Institute
Boston, MA

A. Keith Stewart, MBChB, MBA
Mayo Clinic
Scottsdale, AZ

Speakers:

Jesus G. Berdeja, MD
Sarah Cannon Research Institute
Nashville, TN

Nina Shah, MD
University of California San Francisco
San Francisco, CA

Peter M. Voorhees, MD
University of North Carolina
Chapel Hill, NC

Katja Weisel, MD
University Hospital of Tuebingen
Tuebingen, Germany

Contact:

Karen Tenaglia
RedMedEd
Phone: 609-558-7775
Email: ktenaglia@redmeded.com

back to top

Precision and Emerging Medicine for Hematological Diseases

Friday, December 8, 2017, 7:00 a.m. - 11:00 a.m.
Georgia World Congress Center, Bldg B- Lvl 4- B401-B402

Register now

This program is sponsored by The Leukemia and Lymphoma Society, Postgraduate Institute for Medicine, and RMEI Medical Education, LLC, and is supported by Abbvie, Inc., Amgen, Inc., AstraZeneca Pharmaceuticals LP/Acerta Pharma, and Celgene Corporation.

The symposium will directly address the most relevant information available at the time of the presentation with regard to:

  • Technological advances in molecular techniques for the diagnosis and monitoring of hematologic malignancies
  • The latest research and development in emerging therapies for the treatment of leukemia, lymphoma, and myeloma
  • Key factors related to applying precision medicine for hematologic malignancies in clinical practice

Chair:

Steven T. Rosen, MD
City of Hope National Medical Center
Duarte, CA

Speakers:

Sandeep Dave, MD
Duke University School of Medicine
Durham, NC

Jonathan J. Keats, PhD
Translational Genomics Research Institute
Phoenix, AZ

Karen L. Kaul, MD, PhD
NorthShore University HealthSystem
Evanston, IL

Cheryl L. Willman, MD
University of New Mexico Cancer Center
Albuquerque, NM

Anas Younes, MD
Memorial Sloan Kettering Cancer Center
New York, NY

John Chan, MD
City of Hope
Duarte, CA

Contact:

Cherie Haley
RMEI Medical Education, LLC
Phone: 856-672-3262
Email: chaley@rmei.com

back to top